1.24
Precedente Chiudi:
$1.25
Aprire:
$1.26
Volume 24 ore:
981.47K
Relative Volume:
0.55
Capitalizzazione di mercato:
$142.11M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.7515
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
+9.73%
1M Prestazione:
+6.90%
6M Prestazione:
-6.77%
1 anno Prestazione:
-77.04%
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.24 | 143.29M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
2023-01-06 | Downgrade | Stifel | Buy → Hold |
2023-01-06 | Downgrade | Truist | Buy → Hold |
2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
2022-12-15 | Iniziato | Goldman | Sell |
2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
2022-10-10 | Iniziato | Canaccord Genuity | Buy |
2022-08-18 | Ripresa | Wells Fargo | Overweight |
2022-07-28 | Iniziato | Needham | Hold |
2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | Iniziato | Robert W. Baird | Neutral |
2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
2021-12-07 | Iniziato | Cowen | Outperform |
2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
2021-04-26 | Ripresa | Jefferies | Buy |
2021-02-26 | Iniziato | BofA Securities | Buy |
2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
2020-05-13 | Iniziato | H.C. Wainwright | Buy |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | Reiterato | Mizuho | Buy |
2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
2019-11-12 | Iniziato | SunTrust | Buy |
2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
2019-10-01 | Iniziato | Stifel | Buy |
2019-08-09 | Iniziato | BTIG Research | Buy |
2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
2019-07-12 | Iniziato | Oppenheimer | Outperform |
2019-06-13 | Iniziato | Mizuho | Buy |
2019-06-07 | Iniziato | ROTH Capital | Neutral |
2019-05-31 | Iniziato | Guggenheim | Buy |
2019-05-24 | Ripresa | Citigroup | Buy |
2019-03-28 | Iniziato | SVB Leerink | Outperform |
2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
2018-11-05 | Iniziato | Jefferies | Buy |
2018-08-01 | Iniziato | Citigroup | Buy |
2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
What drives Fate Therapeutics Inc. stock priceFree Market Dynamics Reports - Autocar Professional
How Fate Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser
What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional
Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com
why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser
what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth (ADIA, FATE, MESO, CRSP) - FinancialContent
Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest
H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener
Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st
Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com
TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World
Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus
Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance
Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):